Powder: -20°C for 3 years | In solvent: -80°C for 1 year
hnRNPK-IN-1 is a specific ligand that binds to the heterogeneous nuclear ribonucleoprotein K (hnRNPK) with high affinity, evidenced by Kd values of 4.6 μM and 2.6 μM determined using surface plasmon resonance (SPR) and microscale thermophoresis (MST), respectively. This binding event leads to the disruption of hnRNPK's interaction with the c-myc promoter, resulting in the inhibition of c-myc transcription. Additionally, hnRNPK-IN-1 induces apoptosis in Hela cells and exhibits potent anti-tumor activities[1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 3,770 | 5日内发货 | ||
5 mg | ¥ 4,570 | 5日内发货 | ||
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | hnRNPK-IN-1 is a specific ligand that binds to the heterogeneous nuclear ribonucleoprotein K (hnRNPK) with high affinity, evidenced by Kd values of 4.6 μM and 2.6 μM determined using surface plasmon resonance (SPR) and microscale thermophoresis (MST), respectively. This binding event leads to the disruption of hnRNPK's interaction with the c-myc promoter, resulting in the inhibition of c-myc transcription. Additionally, hnRNPK-IN-1 induces apoptosis in Hela cells and exhibits potent anti-tumor activities[1]. |
靶点活性 | hnRNPK:2.6 μM (Kd), hnRNPK:4.6 μM (Kd), MST assay:2.6 μM (Kd), SPR assay:4.6 μM (Kd) |
体外活性 | hnRNPK-IN-1 (Compound 25; 1.25-5 μM; 24 hours) treatment induces Hela cells apoptosis could be due to its repression of cmyc transcription[1].hnRNPK-IN-1 (1.25-5 μM; 48 hours) treatment down-regulates c-myc gene transcription and expression in Hela cells in a dose-dependent manner[1].hnRNPK-IN-1 shows a selective anti-proliferative effect on human cancer cell lines (Siha, A549, Hela, U2OS, A375, HuH7 and HEK293 cells) with IC50 values ranged from 1.36 to 3.59 μM[1].hnRNPK-IN-1 could selectively bind to hnRNP K without significant interaction with c-myc promoter DNA. The binding of hnRNPK-IN-1 to hnRNP K could disrupt the interaction between hnRNP K and c-myc promoter DNA in vitro and in cells[1]. |
体内活性 | hnRNPK-IN-1 (Compound 25; 6.7-20 mg/kg; i.p.; once a day; for three weeks) exhibits good tumor growth inhibition in a Hela xenograft tumor model[1]. |
分子量 | 419.43 |
分子式 | C23H21N3O5 |
CAS No. | 2313528-04-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (11.92 mM), Sonication and heating to 80℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3842 mL | 11.9209 mL | 23.8419 mL | 59.6047 mL |
5 mM | 0.4768 mL | 2.3842 mL | 4.7684 mL | 11.9209 mL | |
10 mM | 0.2384 mL | 1.1921 mL | 2.3842 mL | 5.9605 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
hnRNPK-IN-1 2313528-04-8 hnRNPK IN 1 hnRNPKIN1 Inhibitor inhibitor inhibit